All In Biotech

Investigational drug · Phase 2

HB0043

Not approved by FDA. In 2 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Acne Vulgaris, Hidradenitis Suppurativa.

Phase 2

Last checked: Nov 19, 2026Latest source record: Mar 4, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations

Highest phase

Phase 2

Industry-sponsored trials

Phase 2 and 3 trials

2

2 still active

All registered trials

3

Any phase or sponsor naming "HB0043"

First trial start

2025

Mar 19, 2025

Sponsors

Lead sponsors of its Phase 2 and 3 trials.

All registered trials by phase

Every ClinicalTrials.gov drug study naming "HB0043", any sponsor or status.

Conditions studied

As listed on its trial records.

  • Acne Vulgaris
  • Hidradenitis Suppurativa

Approved drugs for the same conditions: Hidradenitis suppurativa · Acne · Immunology and inflammation · Dermatology

Largest trials

Live from ClinicalTrials.gov: studies naming "HB0043" as an intervention, largest first.

All trials

Newest research

PubMed records naming it or its code names, newest first.

All 2 on PubMed

Also in development for Acne Vulgaris

  • DenifanstatPhase 31 trial

    Sagimet Biosciences Inc. · Acne Vulgaris

  • DMT310Phase 31 trial

    Dermata Therapeutics · Acne Vulgaris

  • B244Phase 21 trial

    AOBiome LLC · Acne Vulgaris

Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.